Cereno Scientific Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Cereno Scientific ha un patrimonio netto totale di SEK230.7M e un debito totale di SEK90.4M, che porta il suo rapporto debito/patrimonio netto a 39.2%. Le sue attività totali e le sue passività totali sono rispettivamente SEK345.3M e SEK114.6M.

Informazioni chiave

39.2%

Rapporto debito/patrimonio netto

SEK 90.40m

Debito

Indice di copertura degli interessi	n/a
Contanti	SEK 73.84m
Patrimonio netto	SEK 230.73m
Totale passività	SEK 114.55m
Totale attività	SEK 345.28m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( SEK78.5M ) di 4A1 superano le sue passività a breve termine ( SEK24.2M ).

Passività a lungo termine: Le attività a breve termine di 4A1 ( SEK78.5M ) non coprono le sue passività a lungo termine ( SEK90.4M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 7.2% ) di 4A1 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 4A1 è aumentato da 0.6% a 39.2% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 4A1 ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: 4A1 ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 39.4 % ogni anno

Cereno Scientific Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014

Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025

Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014

Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Cereno Scientific AB Announces New Preclinical Data for Cereno Scientific's Novel IP Receptor Agonist CS585 Presented at ESC Congress 2024

Cereno Scientific Receives Orphan Medicinal Product Designation in the Eu for Cs1 in Rare Disease Pulmonary Arterial Hypertension

Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2025

Cereno Scientific Expands Patent Protection for PAH Drug Candidate CS1's Third Patent Family in Brazil

First Subject Dosed in Cereno Scientifics First-In-Human Phase I Trial of Novel Hdac Inhibitor Cs014

Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014

Cereno Scientific AB (publ) to Report Q1, 2025 Results on May 22, 2025

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Cereno Scientific AB (Publ) Approves Election of New Directors

Cereno Scientific AB Submits Clinical Trial Application (CTA) for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Appoints Don De Bethizy as Board of Directors

Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH

New minor risk - Market cap size

Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D

Cereno Scientific AB (publ) Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities

Cereno Scientific AB Appoints Julia Fransson as Director of Business Development

Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension

Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director

Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH

Cereno Scientific AB (publ) to Report Q3, 2024 Results on Nov 21, 2024

Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting

Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585

Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study

Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family

Cereno Scientific AB (Publ) Move to Request “Compassionate Use” of CS1 for Treatment of Patients with Rare Disease PAH

Third quarter 2023 earnings released

Cereno Scientific Reports Significant Progress and A Time Time Adjustment in the Phase II Study of CS1 in Rare Disease PAH

Cereno Scientific AB (publ) Appoints Jeppe Øvlesen as a New Board Member

Cereno Scientific AB (Publ) Reports Positive Results from the Data Quality Control Review Initiative in the Phase II Study of CS1 in Rare Disease Pul Arterial Hypertension (PAH)

Cereno Scientific Announces Appointments to the Nomination Committee Ahead of the Annual General Meeting 2024

New major risk - Shareholder dilution

Second quarter 2023 earnings released

Cereno Scientific to Open Two New Clinics to Complete Patient Recruitment in the Phase II Study of CS1 in Pah

Cereno Scientific AB (Publ) Appoints Eva Jagenheim as Chief Financial Officer

Cereno Scientific Reports Positive Data from Patient Case Study

Chairperson recently bought €68k worth of stock

Cereno Scientific Reports an Investigator-Initiated Patient Case Study from the Ongoing Phase II Study of CS1 in PAH

Cereno Scientific AB (publ), Annual General Meeting, Jun 03, 2024

Cereno Scientific Shares Progress Update in the Phase II Study with Drug Candidate CS1 in the Rare Disease PAH

Cereno Scientific's Phase II Study in the Rare Disease PAH Reports Two Patients Successfully Completed the Treatment Period with Drug Candidate CS1

Full year 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in FY 2021)

Full year 2022 earnings released: kr0.26 loss per share (vs kr0.15 loss in FY 2021)

Cereno Scientific AB (publ) Reports Progress with CS1 Phase II Study in Pulmonary Arterial Hypertension

Cereno Scientific AB (publ) to Report Nine Months, 2023 Results on Nov 17, 2023

Cereno Scientific AB (Publ) Appoints Etienne Adriansen to Chief Business Officer, as of March 1, 2023

Cereno Scientific Announces Changes in the Executive Management Team

Cereno Scientific Reports Six Activated Clinical Sites and Updated Timeline in the Phase II Study in PAH with Drug Candidate CS1

Cereno Scientific AB (Publ) Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr0.069 loss per share (vs kr0.047 loss in 3Q 2021)

No independent directors

Cereno Scientific's Patent Protection for Drug Candidate CS1 Expands in Mexico Through Its Second Patent Family

Second quarter 2022 earnings released

Cereno Scientific Reports First Patient Dosed in Phase II Study in PAH with Drug Candidate CS1

Cereno Scientific's Innovative Phase II Study Design in PAH with CS1 is Accepted for Presentation at the CHEST Annual Meeting on Oct. 16-19 in Nashville, US

Cereno Scientific Announces Enrolling the First Patient in Its Phase II Clinical Study with Lead Drug Candidate Cs1 in Pulmonary Arterial Hypertension

Cereno Scientific Reports First Patient Enrolled in Phase II Study in PAH with Drug Candidate CS1

Frejs Revisorer AB Announces Board Appointments

Cereno Scientific AB Appoints Nick Oakes as Head of Preclinical Development

Cereno Scientific AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

First quarter 2022 earnings released

Cereno Scientific's Abstract on CS1's Innovative Phase II Study Design Accepted At Top Pulmonary Vascular Congress PVRI Held in June, 2022

Cereno Scientific to Present Candidate Drug CS585 Preclinical Data At EHA 2022 - the Premier Medical Congress for Hematology

Cereno Scientific Nominates Drug Candidate CS585 in PCA Program for Continued Development in Cardiovascular Disease